Condition (MeSH)
Endophthalmitis
ClinicalTrials.gov lists 57 trials for Endophthalmitis or a narrower condition beneath it. National Eye Institute (NEI) has the most among industry and government lead sponsors, with 2.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase (log scale)
57 of the 57 trials are tagged with Endophthalmitis itself; the rest are tagged with a narrower condition beneath it.
When did Endophthalmitis trials start? (23)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 1 trial is registered to start in 2027 or later, and not listed here.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 6
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2025 | 3 |
| 2024 | 6 |
| 2023 | 3 |
| 2022 | 2 |
| 2021 | 2 |
| 2020 | 5 |
| 2019 | 4 |
| 2018 | 6 |
| 2017 | 3 |
| 2015 | 3 |
Showing 10 of 23 earlier years.
No forecast is made for this condition: it averages 3.2 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 3 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Endophthalmitis trials in? (8)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 1 |
| Phase 1/2 | 3 |
| Phase 2 | 4 |
| Phase 2/3 | 1 |
| Phase 3 | 4 |
| Phase 4 | 10 |
| Not applicable | 13 |
| Observational | 21 |
How many Endophthalmitis trials are recruiting? (8)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 3 |
| Recruiting | 3 |
| Active, not recruiting | 2 |
| Completed | 30 |
| Suspended | 1 |
Showing 5 of 8 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Endophthalmitis trials? (3)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| National Eye Institute (NEI) | 2 |
| Azienda USL Reggio Emilia - IRCCS | 1 |
| Biogen | 1 |
Which drugs are being tested for Endophthalmitis? (1)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Cefuroxime | 2 |
Interventions as named in the registry (14)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| C: moxifloxacin | 10 |
| No injection of moxifloxacin | 1 |
| Levofloxacin Ophthalmic | 1 |
| Topical antibiotics following injection | 1 |
| Hypochlorous Acid Gel 0.02% | 1 |
Showing 5 of 14 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which publications cover Endophthalmitis? (187)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Endophthalmitis in Eyes Treated with the Port Delivery System with Ranibizumab: Summary of Cases during Clinical Trial Development. | Ophthalmology. Retina | 2025 | Yes |
| The Effect of Metagenomic Sequencing on Patient Clinical Outcomes for Intraocular Infections: A Multicenter Randomized Controlled Trial. | American journal of ophthalmology | 2025 | Yes |
| Complement inhibitors for age-related macular degeneration. | The Cochrane database of systematic reviews | 2023 | Yes |
| Safety of office-based lens surgery: U.S. multicenter study. | Journal of cataract and refractive surgery | 2023 | Yes |
| Complications of intravitreal injections: 2022. | Current opinion in ophthalmology | 2022 | Yes |
Showing 5 of 187 publications.
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Endophthalmitis | 199323 | Exact | Orphadata Science knowledge files, Product 1 |
| Endophthalmitis | 199323 | Exact | Orphanet Rare Disease Ontology (ORDO) |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: serious adverse events in this condition's trials, prevalence, and sub-conditions in mesh.